Print page

Affibody signs distribution agreement with Funakoshi

Affibody, a Swedish biotechnology and biotherapy company, and Funakoshi, a leading provider of research reagents and instruments for researchers in life science fields in Japan, today announced an agreement in which Funakoshi will promote and distribute products from Affibody's portfolio of biotechnology research reagents to the Japanese market.

"We are delighted with this distribution agreement, Affibody's exciting new class of affinity ligands complement our range of top quality products and will enable us to meet the high demand for research reagents in Japan" said Dr. Ryoya Funakoshi, President & CEO of Funakoshi Co., Ltd. Torben Jørgensen, CEO of Affibody, added: "Funakoshi has an excellent reputation on the Japanese market and we appreciate that Funakoshi Co., Ltd. operates as our distributor as it opens up an important sales channel for Affibody. We look forward to a fruitful and long-lasting cooperation".


About Funakoshi

Funakoshi Co., Ltd. has contributed as a leader to distribute research reagents and instruments for researchers in life science fields since its foundation. The mission of Funakoshi is offering many useful tools with leading edge technologies for Japanese researchers from all over the world to support and develop their research. For more information, visit Funakoshi's website: www.funakoshi.co.jp.